PETMED EXPRESS INC
PETSNasdaqConsumer Discretionary · Retail-Drug Stores and Proprietary Stores · FL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $227.0M | $274.1M | $247.6M | $67.4M | $309.2M | $284.1M |
| Operating income | −$1.5M | −$8.2M | $6.1M | $25.7M | $37.6M | $31.0M |
| Net income | −$6.3M | −$7.5M | $5.1M | $21.1M | $30.6M | $25.9M |
| Total assets | $148.7M | $169.9M | $167.5M | $176.3M | $187.5M | $155.3M |
| Total liabilities | $63.6M | $73.2M | $57.5M | $34.1M | $46.2M | $25.3M |
| Equity | $85.1M | $96.7M | $110.0M | $142.2M | $141.3M | $130.0M |
| EPS (diluted) | $-0.30 | $-0.37 | $0.25 | $1.04 | $1.52 | $1.29 |
| Shares out. | 21.0M | 20.6M | 21.2M | 21.0M | 20.3M | 20.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −0.7%
- Net margin
- −2.8%
- Return on equity
- −7.4%
- Return on assets
- −4.2%
- Return on capital (ROCE)
- −1.8%
- Liabilities / assets
- 42.7%
- Debt / equity
- 0.75×
- Book value / share
- $4.05
- Revenue growth (YoY)
- −17.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.51safe
- Accruals / assets
- −7.4%clean
- Beneish M-Score
- -3.09normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 12, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 11, 2025
- NT 10-Kmissed a reporting deadline ↗Jun 16, 2025
- NT 10-Qmissed a reporting deadline ↗Feb 9, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Diveroli Investment Group LlcActivist (13D)Feb 11, 2026
- Silvercape Investments LtdActivist (13D)Dec 11, 2025
- Hotchkis & Wiley Capital Management LlcPassive (13G)Feb 14, 2025
- Vanguard Group IncPassive (13G)Jan 31, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Fulgoni GianDirector | Jan 21, 2026 | D | 26,057 | $0.00 |
| Fulgoni GianDirector | Oct 30, 2025 | Grant | 33,846 | $0.00 |
| Krulik DouglasOfficer — CAO and Interim CFO | Oct 30, 2025 | Grant | 20,000 | $0.00 |
| Lacamp JamesDirector | Oct 30, 2025 | Grant | 34,866 | $0.00 |
| Mennen Justin L.Director | Oct 30, 2025 | Grant | 33,846 | $0.00 |
| Solivan LeahDirector | Oct 30, 2025 | Grant | 33,846 | $0.00 |
| Batushansky PeterDirector | Oct 30, 2025 | Grant | 33,846 | $0.00 |
| Krulik DouglasOfficer — Chief Accounting Officer | Sep 9, 2025 | Grant | 10,000 | $0.00 |
| Krulik DouglasOfficer — Chief Accounting Officer | Sep 27, 2024 | Grant | 40,000 | $0.00 |
| Silvercape Investments Ltd10% owner | Aug 13, 2025 | Buy | 101,000 | $3.17 |
| Silvercape Investments Ltd10% owner | Aug 1, 2025 | Buy | 118,200 | $3.21 |
| Nina Capital Holdings Inc.10% owner | Jul 21, 2025 | Buy | 25,000 | $3.50 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 579,291 | 10.7 | -8.8% |
| Apr 30, 2026 | 635,530 | 7.9 | -21.7% |
| Apr 15, 2026 | 811,886 | 9.9 | +12.2% |
| Mar 31, 2026 | 723,702 | 9.1 | -6.5% |
| Mar 13, 2026 | 774,341 | 7.4 | -27.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Item 5.08May 21, 2026
- Shareholder voteJan 23, 2026
- Changed auditorDec 9, 2025
- Entered a material agreement · Modified shareholder rights · Director / officer change · Other material eventNov 26, 2025
- Results of operations · Delisting / listing-standard noticeNov 13, 2025
- Director / officer change · Regulation FD disclosureOct 21, 2025
- Results of operationsOct 14, 2025
- Material impairment · Prior financials not reliable (restatement) · Other material eventOct 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.